BackgroundAlthough high dose of antimony is the mainstay for treatment of American cutaneous leishmaniasis (ACL), ongoing major concerns remain over its toxicity. Whether or not low dose antimony regimens provide non-inferior effectiveness and lower toxicity has long been a question of dispute.MethodsA single-blind, non-inferiority, randomized controlled trial was conducted comparing high dose with low dose of antimony in subjects with ACL treated at a referral center in Rio de Janeiro, an endemic area of Leishmania (Viannia) braziliensis transmission. The primary outcome was clinical cure at 360 days of follow-up in the modified-intention-to-treat (mITT) and per-protocol (PP) populations. Non-inferiority margin was 15%. Secondary objectives included occurrence of epithelialization, adverse events and drug discontinuations. This study was registered in ClinicalTrials.gov: NCT01301924.ResultsOverall, 72 patients were randomly assigned to one of the two treatment arms during October 2008 to July 2014. In mITT, clinical cure was observed in 77.8% of subjects in the low dose antimony group and 94.4% in the high dose antimony group after one series of treatment (risk difference 16.7%; 90% CI, 3.7–29.7). The results were confirmed in PP analysis, with 77.8% of subjects with clinical cure in the low dose antimony group and 97.1% in the high dose antimony group (risk difference 19.4%; 90% CI, 7.1–31.7). The upper limit of the confidence interval exceeded the 15% threshold and was also above zero supporting the hypothesis that low dose is inferior to high dose of antimony after one series of treatment. Nevertheless, more major adverse events, a greater number of adverse events and major adverse events per subject, and more drug discontinuations were observed in the high dose antimony group (all p<0.05). Interestingly, of all the subjects who were originally allocated to the low dose antimony group and were followed up after clinical failure, 85.7% achieved cure after a further treatment with local therapy or low dose of antimony.ConclusionsCompared with high dose, low dose of antimony was inferior at the pre-specified margin after one series of treatment of ACL, but was associated with a significantly lower toxicity. While high dose of antimony should remain the standard treatment for ACL, low dose antimony treatment might be preferred when toxicity is a primary concern.
A case-control study was conducted to examine the association among
the Montenegro skin test (MST), age of skin lesion and therapeutic
response in patients with cutaneous leishmaniasis (CL) treated at
Evandro Chagas National Institute of Infectious Diseases (INI),
Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. For each
treatment failure (case), two controls showing skin lesion healing
following treatment, paired by sex and age, were randomly selected. All patients
were treated with 5 mg Sb5+/kg/day of intramuscular
meglumine antimoniate (Sb5+) for 30 successive days.
Patients with CL were approximately five times more likely to fail when lesions
were less than two months old at the first appointment. Patients with treatment
failure showed less intense MST reactions than patients progressing to clinical
cure. For each 10 mm of increase in MST response, there was a 26% reduction
in the chance of treatment failure. An early treatment - defined as a treatment
applied for skin lesions, which starts when they are less than two months old at
the first appointment -, as well as a poor cellular immune response, reflected
by lower reactivity in MST, were associated with treatment failure in cutaneous
leishmaniasis.
Background Atypical presentations of cutaneous leishmaniasis include sporotrichoid leishmaniasis (SL), which is clinically described as a primary ulcer combined with lymphangitis and nodules and/or ulcerated lesions along its pathway.Aims To assess the differences between patients with sporotrichoid leishmaniasis and typical cutaneous leishmaniasis (CL).Methods From January 2004 to December 2010, 23 cases of SL (4.7%) were detected among 494 CL patients diagnosed at a reference center for the disease in Rio de Janeiro State, Brazil. These 23 cases were compared with the remaining 471 patients presenting CL.Results SL predominated in female patients (60.9%, p = 0.024), with older age (p = 0.032) and with lesions in upper limbs (52.2%, p = 0.028). CL affected more men (64.5%), at younger age, and with a higher number of lesions exclusively in lower limbs (34.8%).Conclusions Differences in clinical and epidemiological presentation were found between SL patients as compared to CL ones, in a region with a known predominance of Leishmania (Viannia) braziliensis. The results are similar to the features of most of the sporotrichosis patients as described in literature, making the differential diagnosis between ATL and sporotrichosis more important in overlapping areas for both diseases, like in Rio de Janeiro State.
SUMMARY American tegumentary leishmaniasis is an infectious disease caused by a protozoan of
the genus Leishmania. Pentavalent antimonials are the first choice
drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a
clinical trial for CL we investigated the occurrence of pancreatic toxicity with
different schedules of treatment with meglumine antimoniate (MA). Seventy-two
patients were allocated in two different therapeutic groups: 20 or 5 mg of
pentavalent antimony (Sb5+)/kg/day for 20 or 30 days, respectively.
Looking for adverse effects, patients were asked about abdominal pain, nausea,
vomiting or anorexia in each medical visit. We performed physical examinations and
collected blood to evaluate serum amylase and lipase in the pre-treatment period, and
every 10 days during treatment and one month post-treatment. Hyperlipasemia occurred
in 54.8% and hyperamylasemia in 19.4% patients. Patients treated with MA 20 mg
Sb5+ presented a higher risk of hyperlipasemia (p =
0.023). Besides, higher MA doses were associated with a 2.05 higher risk ratio
(p = 0.003) of developing more serious (moderate to severe)
hyperlipasemia. The attributable fraction was 51% in this group. Thirty-six patients
presented abdominal pain, nausea, vomiting or anorexia but only 47.2% of those had
hyperlipasemia and/ or hyperamylasemia. These findings suggest the importance of the
search for less toxic therapeutic regimens for the treatment of CL.
We report 2 cases of patients with immune reconstitution infl ammatory syndrome (IRIS) associated with cutaneous disseminated sporotrichosis and human immunodefi ciency virus (HIV) coinfection. The patients received specifi c treatment for sporotrichosis. However, after 4 and 5 weeks from the beginning of antiretroviral therapy, both patients experienced clinical exacerbation of skin lesions despite increased T CD4+ cells (T cells cluster of differentiation 4 positive) count and decreased viral load. Despite this exacerbation, subsequent mycological examination after systemic corticosteroid administration did not reveal fungal growth. Accordingly, they were diagnosed with IRIS. However, the sudden withdrawal of the corticosteroids resulted in the recurrence of IRIS symptoms. No serious adverse effects could be attributed to prednisone. We recommend corticosteroid treatment for mildto-moderate cases of IRIS in sporotrichosis and HIV coinfection with close follow-up.
Background
American tegumentary leishmaniasis (ATL) is a neglected disease with wide territorial distribution. Knowledge is scarce in children and adolescents. This study aims to compare the clinical features and response to antimony treatment in pediatric and adult patients with cutaneous leishmaniasis.
Methods
A retrospective cohort study was performed with 659 patients who attended a reference centre in Rio de Janeiro, Brazil, from 2000 to 2015. The pediatric cohort consisted of 131 (20%) patients and the adult cohort consisted of 528 (80%) patients.
Results
The epidemiological profile, antimony therapeutic response and incidence of adverse events (AE) were different in the pediatric cohort compared with the adult cohort. Mucosal form was less frequent in the pediatric cohort (RR:0.49, p=0.011). Lesions in the head, neck and trunk were more frequent in the pediatric cohort (RR:1.49, p=0.043). The effectiveness of antimony treatment was superior in the pediatric cohort (88.3% vs 76.6%) with a shorter healing time (RR:0.49, p=0.009). Pediatric patients had lower proportions of moderate to severe AE compared with adults (RR:0.45, p=0.027). Clinical AE predominated in the adult cohort (RR:0.40, p=0.000) and laboratory AE in the pediatric cohort (RR:1.50, p=0.023).
Conclusions
This study adds to the body of knowledge on differences that exist between different age groups in ATL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.